HRP20230566T1 - Liposomalna formulacija za podmazivanje zglobova - Google Patents
Liposomalna formulacija za podmazivanje zglobova Download PDFInfo
- Publication number
- HRP20230566T1 HRP20230566T1 HRP20230566TT HRP20230566T HRP20230566T1 HR P20230566 T1 HRP20230566 T1 HR P20230566T1 HR P20230566T T HRP20230566T T HR P20230566TT HR P20230566 T HRP20230566 T HR P20230566T HR P20230566 T1 HRP20230566 T1 HR P20230566T1
- Authority
- HR
- Croatia
- Prior art keywords
- range
- joint
- dmpc
- composition according
- membrane
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 15
- 238000009472 formulation Methods 0.000 title 1
- 238000005461 lubrication Methods 0.000 title 1
- 239000012528 membrane Substances 0.000 claims 14
- GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 8
- 239000002502 liposome Substances 0.000 claims 8
- 150000003904 phospholipids Chemical group 0.000 claims 8
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 7
- 229930195725 Mannitol Natural products 0.000 claims 7
- 150000002327 glycerophospholipids Chemical class 0.000 claims 7
- 235000010355 mannitol Nutrition 0.000 claims 7
- 239000000594 mannitol Substances 0.000 claims 7
- 201000008482 osteoarthritis Diseases 0.000 claims 5
- 230000007704 transition Effects 0.000 claims 5
- 208000012659 Joint disease Diseases 0.000 claims 4
- 239000000872 buffer Substances 0.000 claims 4
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 229920005862 polyol Polymers 0.000 claims 2
- 150000003077 polyols Chemical class 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 230000001256 tonic effect Effects 0.000 claims 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 1
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 claims 1
- LJARBVLDSOWRJT-PSXMRANNSA-N 1,2-di-O-pentadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCC LJARBVLDSOWRJT-PSXMRANNSA-N 0.000 claims 1
- 208000006820 Arthralgia Diseases 0.000 claims 1
- 208000025978 Athletic injury Diseases 0.000 claims 1
- 206010060820 Joint injury Diseases 0.000 claims 1
- 206010023230 Joint stiffness Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010041738 Sports injury Diseases 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 229960003160 hyaluronic acid Drugs 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000007794 irritation Effects 0.000 claims 1
- 210000000629 knee joint Anatomy 0.000 claims 1
- 239000002953 phosphate buffered saline Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 229930195734 saturated hydrocarbon Natural products 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 230000008736 traumatic injury Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/22—Lipids, fatty acids, e.g. prostaglandins, oils, fats, waxes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/10—Materials for lubricating medical devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/06—Materials or treatment for tissue regeneration for cartilage reconstruction, e.g. meniscus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/24—Materials or treatment for tissue regeneration for joint reconstruction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (15)
1. Farmaceutski sastav koji sadrži:
neionsko sredstvo za toničnost koje sadrži poliol manitol; i
liposome koji sadrže najmanje jednu membranu koja sadrži najmanje jedan fosfolipid (PL) odabran među glicerofosfolipidima (GPL), pri čemu navedeni GPL ima dva ugljikovodična lanca C12-C18, koji su isti ili različiti, i sfingomijelin (SM) koji ima ugljikovodični lanac C12-C18 pri čemu najmanje jedna membrana ima temperaturu faznog prijelaza unutar raspona od 20 °C do 39 °C;
pri čemu je farmaceutski sastav u osnovi bez dodatnog farmaceutski aktivnog sredstva.
2. Sastav prema patentnom zahtjevu 1:
i.) koji sadrži tekući medij u kojem su suspendirani liposomi, pri čemu je navedeni tekući medij odabran između pufera i vode po izboru, pri čemu je navedeni pufer odabran između histidinskog pufera i fosfatno puferirane fiziološke otopine po izboru;
ii.) pri čemu je manitol prisutan u farmaceutskom sastavu u masenom postotku unutar raspona od 0,1 % (m/m) do 7 % (m/m);
iii.) koji ima osmolalnost unutar raspona od 200 do 600 mOsm, koji po izboru ima osmolalnost od 300 mOsm, i/ili;
iv.) koji ima pH-vrijednost unutar raspona od 5 – 8
3. Sastav prema patentnom zahtjevu 1, pri čemu je maseni omjer liposoma i manitola unutar raspona od 6 : 1 do 2 : 1.
4. Sastav prema bilo kojem od patentnih zahtjeva 1 do 3, pri čemu:
i.) su navedeni liposomi multilamelarne vezikule (MLV);
ii.) navedeni GPL sadrži dva acilna lanca C14, C15, C16ili C18, i/ili;
iii.) najmanje jedan od navedenih ugljikovodičnih lanaca je zasićeni ugljikovodični lanac, pri čemu su po izboru dva ugljikovodična lanca zasićena.
5. Sastav prema bilo kojem od patentnih zahtjeva 1 do 4, pri čemu je navedeni PL fosfatidilkolin (PC).
6. Sastav prema patentnom zahtjevu 5, pri čemu najmanje jedna navedena membrana sadrži 1,2-dimiristoil-sn-glicero-3-fosfokolin (DMPC).
7. Sastav prema patentnom zahtjevu 6, pri čemu najmanje jedna navedena membrana sadrži PC odabran iz skupine koja se sastoji od 1,2-dipalmitoil-sn-glicero-3-fosfokolina (DPPC), 1,2-dipentadekanoil-sn-glicero- 3-fosfokolina (C15), 1,2-distearoil-sn-glicero-3-fosfokolina (DSPC) i SM koji ima ugljikovodični lanac C16 (D-eritro C16).
8. Sastav prema patentnom zahtjevu 7, pri čemu:
i.) je molski udio DMPC-a u najmanje jednoj membrani unutar raspona od 10 % do 75 %;
ii.) da najmanje jedna navedena membrana sadrži DMPC i DPPC, pri čemu je molski postotni omjer DMPC-a i DPPC-a unutar raspona od 25 : 75 do 70 : 30 po izboru, pri čemu je molski postotni omjer DMPC-a i DPPC-a 45 : 55, po izboru;
iii.) najmanje jedna navedena membrana sadrži DMPC i C15, pri čemu je molski postotni omjer DMPC-a i C15 unutar raspona od 25 : 75 do 45 : 55, po izboru;
iv.) najmanje jedna navedena membrana sadrži DMPC i DSPC, pri čemu je molski postotni omjer DMPC-a i DSPC-a 75 : 25, po izboru; i/ili
v.) najmanje jedna navedena membrana sadrži DMPC i D-eritro C16, pri čemu je molski postotni omjer DMPC-a i D-eritro C16 unutar raspona od 10 : 90 do 25 : 75, po izboru.
9. Sastav prema patentnom zahtjevu 5, pri čemu najmanje jedna navedena membrana sadrži C15.
10. Sastav prema bilo kojem od patentnih zahtjeva 1 do 9, pri čemu:
i.) je ukupna koncentracija PL-a unutar raspona od 50 do 300 mM;
ii.) su fosfolipidi prisutni u farmaceutskom sastavu u masenom postotku unutar raspona od 0,5 % (m/m) do 30 % (m/m) ukupne mase farmaceutskog sastava;
iii.) liposomi imaju srednji promjer između 0,5 µm i 10 µm;
iv.) najmanje jedna membrana ima temperaturu faznog prijelaza od 30 °C do 35 °C;
v.) je temperatura zgloba unutar raspona od 1 °C do 15 °C iznad navedene temperature faznog prijelaza; i/ili
vi.) u osnovi ne sadrži hijaluronsku kiselinu.
11. Sastav prema patentnom zahtjevu 1, pri čemu sadrži liposome MLV čije se membrane sastoje od DMPC-a i DPPC-a; manitol; i histidinski pufer, pri čemu je DMPC prisutan u farmaceutskom sastavu u masenom postotku unutar raspona od 1 % (m/m) do 10 % (m/m), DPPC je prisutan u masenom postotku unutar raspona od 2 % (m/m) do 12 % (m/m), a manitol je prisutan u masenom postotku unutar raspona od 1 % (m/m) do 7 % (m/m), od ukupne mase farmaceutskog sastava.
12. Sastav prema bilo kojem od patentnih zahtjeva 1 do 11, pri čemu:
i.) jedna dozna jedinica farmaceutskog sastava sadrži od 20 mg do 350 mg manitola i od 50 mg do 1000 mg fosfolipida:
ii.) je u obliku parenteralnog farmaceutskog sastava koji sadrži suspenziju liposoma; i/ili
iii.) je sastav u obliku primjerenom za primjenu koji je odabran iz skupine koja se sastoji od intraartikularne injekcije, artroskopske primjene i kirurške primjene.
13. Sastav prema bilo kojem od patentnih zahtjeva 1 do 12, za upotrebu u liječenju, upravljanju ili prevenciji poremećaja zgloba ili stanja ili simptoma koji proizlaze iz poremećaja zgloba, ili za sprječavanje trošenja zgloba, pri čemu je navedeni poremećaj zgloba ili stanje odabrano iz skupine koja se sastoji od artritisa, osteoartritisa, osteoartritisa u bolesnika s reumatoidnim artritisom, traumatske ozljede zgloba, ukočenog zgloba, sportske ozljede, traumatske ozljede u pogledu osteoartritisa (OA), zgloba nakon artrocenteze, artroskopske kirurgije, otvorene operacije zgloba, zamjene zgloba i psorijatičnog artritisa, po izboru.
14. Sastav prema bilo kojem od patentnih zahtjeva 1 do 13, za upotrebu za smanjenje boli u zglobu koljena u bolesnika s osteoartritisom.
15. Farmaceutski sastav koji sadrži:
neionsko sredstvo za toničnost koje sadrži poliol manitol; i
liposome koji sadrže najmanje jednu membranu koja sadrži najmanje jedan fosfolipid (PL) odabran među glicerofosfolipidima (GPL), pri čemu navedeni GPL ima dva ugljikovodična lanca C12-C18, koji su isti ili različiti, i sfingomijelin (SM) koji ima ugljikovodični lanac C12-C18, pri čemu najmanje jedna membrana ima temperaturu faznog prijelaza unutar raspona od 20 °C do 39 °C;
farmaceutski sastav u osnovi je bez dodatnog farmaceutski aktivnog sredstva,
za upotrebu u liječenju boli ili iritacije u zglobu u osobe koja ima poremećaj zgloba, pri čemu zglob ima temperaturu zgloba koja je iznad temperature faznog prijelaza.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762548429P | 2017-08-22 | 2017-08-22 | |
| EP18847493.6A EP3672653B1 (en) | 2017-08-22 | 2018-08-21 | Liposomal formulation for joint lubrication |
| PCT/IL2018/050923 WO2019038763A1 (en) | 2017-08-22 | 2018-08-21 | LIPOSOMAL FORMULATION FOR JOINT LUBRICATION |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230566T1 true HRP20230566T1 (hr) | 2023-08-18 |
Family
ID=65439381
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230566TT HRP20230566T1 (hr) | 2017-08-22 | 2018-08-21 | Liposomalna formulacija za podmazivanje zglobova |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US11123293B2 (hr) |
| EP (2) | EP3672653B1 (hr) |
| JP (2) | JP7082336B2 (hr) |
| KR (2) | KR102607729B1 (hr) |
| CN (2) | CN114601799B (hr) |
| AU (3) | AU2018319594B2 (hr) |
| BR (1) | BR112020003767B1 (hr) |
| CA (2) | CA3219776A1 (hr) |
| DK (1) | DK3672653T3 (hr) |
| EA (1) | EA202090476A1 (hr) |
| ES (1) | ES2948715T3 (hr) |
| FI (1) | FI3672653T3 (hr) |
| HR (1) | HRP20230566T1 (hr) |
| HU (1) | HUE062030T2 (hr) |
| IL (3) | IL301801B2 (hr) |
| LT (1) | LT3672653T (hr) |
| MA (1) | MA49959B1 (hr) |
| MX (2) | MX2020002041A (hr) |
| MY (1) | MY197149A (hr) |
| PH (1) | PH12020500331A1 (hr) |
| PL (1) | PL3672653T3 (hr) |
| PT (1) | PT3672653T (hr) |
| SG (1) | SG11202000773QA (hr) |
| SI (1) | SI3672653T1 (hr) |
| WO (1) | WO2019038763A1 (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI782181B (zh) * | 2019-02-11 | 2022-11-01 | 以色列商莫比斯醫療有限公司 | 用於關節潤滑的脂質體調配物 |
| JP2021013788A (ja) * | 2020-11-10 | 2021-02-12 | 株式会社三洋物産 | 遊技機 |
| EP4522178A1 (en) | 2023-01-19 | 2025-03-19 | Moebius Medical Ltd. | A long-acting liposomal composition for treatment of pain in articular disorders |
| KR20250018222A (ko) * | 2023-07-26 | 2025-02-05 | 차의과학대학교 산학협력단 | 미토콘드리아가 캡슐화된 세포막 융합유도 리포좀을 포함하는 골관절염 치료를 위한 약학 조성물 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5403592A (en) | 1987-08-25 | 1995-04-04 | Macnaught Pty Limited | Lubricant composition for rheumatism |
| EP0319638A1 (en) * | 1987-12-08 | 1989-06-14 | Estee Lauder Inc. | Liposome containing cosmetic and pharmaceutical compositions and methods for utilizing such compositions |
| US5941909A (en) * | 1995-02-14 | 1999-08-24 | Mentor Corporation | Filling material for soft tissue implant prostheses and implants made therewith |
| AUPN723395A0 (en) | 1995-12-19 | 1996-01-18 | Macnaught Medical Pty Limited | Lubrication methods |
| US6379648B1 (en) * | 1999-02-01 | 2002-04-30 | The Curators Of The University Of Missouri | Biodegradable glass compositions and methods for radiation therapy |
| US6800298B1 (en) | 2000-05-11 | 2004-10-05 | Clemson University | Biological lubricant composition and method of applying lubricant composition |
| EP1353659A1 (de) * | 2001-01-24 | 2003-10-22 | Mestex AG | Verwendung von neurotoxischen substanzen für die herstellung eines mittels zur behandlung von gelenkschmerzen |
| US6509027B2 (en) * | 2001-02-12 | 2003-01-21 | Supergen, Inc. | Injectable pharmaceutical composition comprising coated particles of camptothecin |
| NZ528544A (en) * | 2001-03-29 | 2006-03-31 | Scripps Research Inst | Formulations comprising entrapped active ingredients and uses thereof |
| IL159334A0 (en) * | 2001-06-25 | 2004-06-01 | Yissum Res Dev Co | A method for preparation of vesicles loaded with biological material and different uses thereof |
| US20050123593A1 (en) | 2001-06-25 | 2005-06-09 | Jonathan Thompson | Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints |
| EP1423081A4 (en) | 2001-06-25 | 2005-05-25 | Depuy Int Ltd | COMPOSITION COMPRISING GLYCOSAMINOGLYCANS AND HYALURONIDASE INHIBITORS FOR THE TREATMENT OF ARTHRITIC ARTICULATIONS |
| DE10255106A1 (de) | 2002-11-24 | 2004-06-09 | Novosom Ag | Liposomale Glucocorticoide |
| US7205006B2 (en) | 2003-09-25 | 2007-04-17 | Prime Pharmaceutical Corporation | Mahonia aquifolium extract, extraction process and pharmaceutical composition containing the same |
| ATE411006T1 (de) | 2004-06-03 | 2008-10-15 | Bracco Research Sa | Liposomale anordnung für die therapeutische und/oder diagnostische anwendung |
| JP2008502690A (ja) | 2004-06-15 | 2008-01-31 | アンドリュー シァン チェン， | リン脂質組成物ならびにその調製方法および使用方法 |
| US20070071840A1 (en) | 2005-09-27 | 2007-03-29 | Sridevi Dhanaraj | Method for treatment of cartilage disorders with centella extract |
| ITPD20060202A1 (it) | 2006-05-22 | 2007-11-23 | Univ Degli Studi Trieste | Miscele polimeriche di polisaccaridi anionici e cationici e loro impiego |
| JP5072275B2 (ja) * | 2006-07-03 | 2012-11-14 | テルモ株式会社 | 閉鎖小胞の分離方法、製剤の製造方法および評価方法 |
| US20080027554A1 (en) * | 2006-07-31 | 2008-01-31 | Talmadge Karen D | Kit and methods of treatment of an intervertebral disc |
| EP2079442B1 (en) * | 2006-09-28 | 2016-07-27 | Hadasit Medical Research Services & Development Limited | Use of glycerophospholipids for joint lubrication |
| US8834920B2 (en) | 2006-12-21 | 2014-09-16 | Alza Corporation | Liposome composition for targeting egfr receptor |
| FR2918276B1 (fr) | 2007-07-02 | 2010-01-22 | Anteis Sa | "utilisation d'un gel de polysaccharide(s)naturel(s)pour la preparation d'une formulation injectable de traitement des degenerescences articulaires" |
| EP2254546A4 (en) | 2008-02-20 | 2014-07-09 | Elc Man Llc | TOPICAL COMPOSITIONS AND METHODS FOR LAUNDERING THE SKIN |
| CA2803034A1 (en) * | 2010-06-17 | 2011-12-22 | Jacob Klein | Phosphatidylcholine lipid liposomes as boundary lubricants in aqueous media |
| IL206739A (en) | 2010-06-30 | 2016-06-30 | David Segal | An injectable drug containing silitol as an active substance |
| WO2012143876A1 (en) * | 2011-04-19 | 2012-10-26 | Anteis S.A. | A sterile and injectable aqueous formulation for administration in the intra-articular space of an intra-articular joint |
| US8623839B2 (en) | 2011-06-30 | 2014-01-07 | Depuy Mitek, Llc | Compositions and methods for stabilized polysaccharide formulations |
| GB201206486D0 (en) * | 2012-04-12 | 2012-05-30 | Sequessome Technology Holdings Ltd | Vesicular formulations and uses thereof |
| CA2878152C (en) | 2012-07-05 | 2020-12-29 | Taiwan Liposome Company, Ltd. | Methods of treating arthritis |
| CN104688721A (zh) * | 2014-10-11 | 2015-06-10 | 黄萍 | 一种含紫杉醇脂质体的抗类风湿性关节炎药物凝胶剂及其制备方法 |
-
2018
- 2018-08-21 EA EA202090476A patent/EA202090476A1/ru unknown
- 2018-08-21 SI SI201830942T patent/SI3672653T1/sl unknown
- 2018-08-21 HU HUE18847493A patent/HUE062030T2/hu unknown
- 2018-08-21 ES ES18847493T patent/ES2948715T3/es active Active
- 2018-08-21 HR HRP20230566TT patent/HRP20230566T1/hr unknown
- 2018-08-21 SG SG11202000773QA patent/SG11202000773QA/en unknown
- 2018-08-21 CN CN202210282704.7A patent/CN114601799B/zh active Active
- 2018-08-21 EP EP18847493.6A patent/EP3672653B1/en active Active
- 2018-08-21 KR KR1020207006061A patent/KR102607729B1/ko active Active
- 2018-08-21 CA CA3219776A patent/CA3219776A1/en active Pending
- 2018-08-21 WO PCT/IL2018/050923 patent/WO2019038763A1/en active Application Filing
- 2018-08-21 IL IL301801A patent/IL301801B2/en unknown
- 2018-08-21 KR KR1020237040609A patent/KR20230166148A/ko active Pending
- 2018-08-21 US US16/337,188 patent/US11123293B2/en active Active
- 2018-08-21 CA CA3073368A patent/CA3073368C/en active Active
- 2018-08-21 IL IL272630A patent/IL272630B2/en unknown
- 2018-08-21 IL IL312816A patent/IL312816A/en unknown
- 2018-08-21 MX MX2020002041A patent/MX2020002041A/es unknown
- 2018-08-21 BR BR112020003767-2A patent/BR112020003767B1/pt active IP Right Grant
- 2018-08-21 JP JP2020511447A patent/JP7082336B2/ja active Active
- 2018-08-21 PL PL18847493.6T patent/PL3672653T3/pl unknown
- 2018-08-21 EP EP23160029.7A patent/EP4223284A1/en active Pending
- 2018-08-21 MY MYPI2020000726A patent/MY197149A/en unknown
- 2018-08-21 PT PT188474936T patent/PT3672653T/pt unknown
- 2018-08-21 MA MA49959A patent/MA49959B1/fr unknown
- 2018-08-21 AU AU2018319594A patent/AU2018319594B2/en active Active
- 2018-08-21 DK DK18847493.6T patent/DK3672653T3/da active
- 2018-08-21 LT LTEPPCT/IL2018/050923T patent/LT3672653T/lt unknown
- 2018-08-21 FI FIEP18847493.6T patent/FI3672653T3/fi active
- 2018-08-21 CN CN201880053772.8A patent/CN111065423B/zh active Active
-
2020
- 2020-02-13 PH PH12020500331A patent/PH12020500331A1/en unknown
- 2020-02-21 MX MX2023009082A patent/MX2023009082A/es unknown
-
2021
- 2021-08-15 US US17/445,089 patent/US12214077B2/en active Active
-
2022
- 2022-05-17 JP JP2022080859A patent/JP7383759B2/ja active Active
-
2023
- 2023-05-26 AU AU2023203309A patent/AU2023203309B2/en active Active
-
2024
- 2024-12-17 US US18/984,974 patent/US20250114304A1/en active Pending
-
2025
- 2025-01-07 AU AU2025200077A patent/AU2025200077A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230566T1 (hr) | Liposomalna formulacija za podmazivanje zglobova | |
| US20150037404A1 (en) | Methods for joint lubrication and cartilage wear prevention making use of glycerophospholipids | |
| CN104363894B (zh) | 用于治疗关节疼痛或运动性降低的囊泡制剂 | |
| US20230080018A1 (en) | Phosphatidylcholine lipid liposomes as boundary lubricants in aqueous media | |
| CN108472253A (zh) | 塞来昔布的胃肠外组合物 | |
| EP3373909A1 (en) | Vitamin k-enriched lipid emulsion formulations for the treatment of pharma toxicity | |
| IL173330A (en) | Sterilized by a filter for relief of inflammation, pain or fever and a method of preparing it | |
| NZ761298B2 (en) | Liposomal formulation for joint lubrication | |
| EP1745788A1 (de) | Acylglycerophospholipide zur Behandlung von Krebs und Tumorkachexie | |
| TWI782181B (zh) | 用於關節潤滑的脂質體調配物 | |
| Salvioli et al. | Nucleation and aggregation of cholesterol crystals in the early phase of gallstone genesis | |
| EP1572152A2 (en) | Liposomal analgesic formulation and use |